Van Dijken et al., "H7N9 live attenuated influenza vaccine
is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets," Molecular Therapy, vol.
Considerations for the Use of Live Attenuated Influenza Vaccine
and Inactivated Influenza Vaccine When Either is Available
The unanimous vote belies the desire by some for ACIP to call for a vote on whether live attenuated influenza vaccine
(LAIV) should be recommended preferentially over inactivated influenza vaccine (IIV) for healthy children.
In this military population, the live attenuated influenza vaccine
(LAIV) and the trivalent inactivated vaccine (TIV) showed effectiveness of 22% and 35%, respectively.
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has voted to stop the use of the live attenuated influenza vaccine
for the 2016-2017 flu season.
* Figure 1, "Recommended Immunization Schedule for Persons Aged 0 through 18 Years" was modified to highlight the recommendations for influenza vaccination for children 1) for live attenuated influenza vaccine
, which may only be administered beginning at age 2 years, and 2) for children aged 6 months through 8 years, who need 2 doses of influenza vaccine in the first year vaccinated, and in subsequent years only require 1 dose of vaccine.
The live attenuated influenza vaccine
(LAIV) can now be used starting at 2 years of age.
SAN FRANCISCO -- An experimental refrigerator-stable formulation of the live attenuated influenza vaccine
marketed as FluMist was comparable to the approved frozen formulation in a phase III trial presented in a poster at the annual meeting of the Pediatric Academic Societies.
Live attenuated influenza vaccine
(LAIV) is likely to be an option for all individuals with egg allergies, regardless of allergy severity, because the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to approve proposed amendments to the existing recommendations regarding administration of LAIV in individuals with egg allergies.
seasonal influenza vaccines; 2) vaccine dose considerations for children aged 6 months through 8 years; and 3) a preference for the use, when immediately available, of live attenuated influenza vaccine
(LAIV) for healthy children aged 2 through 8 years, to be implemented as feasible for the 2014-15 season but not later than the 2015-16 season.
FluMist, the live attenuated influenza vaccine
(LAIV), which is administered as an intranasal spray, is now approved for use among those 2 to 4 years of age.